AbbVie Inc. (NYSE:ABBV) Declares Quarterly Dividend of $1.73

AbbVie Inc. (NYSE:ABBV) announced a quarterly dividend on Thursday, June 18th. Stockholders of record on Wednesday, July 15th will be paid a dividend of 1.73 per share on Friday, August 14th. This represents a c) annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Wednesday, July 15th.

AbbVie has raised its dividend by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 53 years. AbbVie has a payout ratio of 49.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect AbbVie to earn $16.30 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 42.5%.

AbbVie Price Performance

ABBV opened at $216.63 on Friday. The stock has a market cap of $382.74 billion, a P/E ratio of 106.71, a P/E/G ratio of 0.68 and a beta of 0.32. The stock’s 50 day simple moving average is $212.08 and its 200 day simple moving average is $218.78. AbbVie has a 1-year low of $181.73 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period last year, the business posted $2.46 EPS. Research analysts expect that AbbVie will post 14.3 EPS for the current fiscal year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.